ZCM
ANIK icon

Ziegler Capital Management’s Anika Therapeutics ANIK Stock Holding History

Ziegler Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$761K Buy
29,943
+1,526
+5% +$36.9K 0.03% 312
2023
Q4 		$644K Hold
28,417
– – 0.03% 333
2023
Q3 		$529K Sell
28,417
-176
-0.6% -$3.65K 0.02% 342
2023
Q2 		$743K Buy
28,593
+9,860
+53% +$264K 0.03% 311
2023
Q1 		$538K Buy
18,733
+184
+1% +$5.48K 0.02% 347
2022
Q4 		$549K Sell
18,549
-5,051
-21% -$144K 0.02% 344
2022
Q3 		$562K Sell
23,600
-134
-0.6% -$3.08K 0.02% 341
2022
Q2 		$530K Buy
23,734
+10,079
+74% +$225K 0.02% 346
2022
Q1 		$343K Sell
13,655
-1,900
-12% -$57.9K 0.01% 347
2021
Q4 		$557K Sell
15,555
-2,761
-15% -$111K 0.02% 366
2021
Q3 		$780K Sell
18,316
-664
-3% -$27.4K 0.03% 351
2021
Q2 		$822K Sell
18,980
-568
-3% -$24.2K 0.03% 352
2021
Q1 		$797K Sell
19,548
-516
-3% -$19.6K 0.03% 355
2020
Q4 		$908K Buy
20,064
+4,629
+30% +$176K 0.03% 328
2020
Q3 		$546K Sell
15,435
-13,462
-47% -$486K 0.02% 366
2020
Q2 		$1.09M Buy
28,897
+4,047
+16% +$133K 0.03% 294
2020
Q1 		$718K Buy
+24,850
New +$1.01M 0.02% 413

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Ziegler Capital Management's ANIK Position: Q1 2024 in Review

Ziegler Capital Management increased its Anika Therapeutics (ANIK) stake by 5.4% in Q1 2024, buying an estimated $36.9K and bringing the position to 29,943 shares worth $761K. The position accounts for 0.03% of the portfolio, ranked #312.

Ziegler Capital Management first reported a position in ANIK in Q1 2020 and has held it in 17 quarters since. The position peaked at $1.09M in Q2 2020. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2024.

  • Ziegler Capital Management held 29,943 shares of Anika Therapeutics worth $761K as of Q1 2024.
  • Ziegler Capital Management bought 1,526 Anika Therapeutics shares in Q1 2024, an estimated $36.9K.
  • Anika Therapeutics made up 0.03% of Ziegler Capital Management's portfolio in Q1 2024, its #312 holding.
  • Ziegler Capital Management first reported a position in Anika Therapeutics in Q1 2020 and has held it in 17 quarters since.
  • Ziegler Capital Management's Anika Therapeutics position peaked at $1.09M in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2024.

Based on Ziegler Capital Management's 13F filing for Q1 2024, filed 15 May 2024.